CA
NZ
UK
AU
IND
US
● It cut itsRevenueoutlook on lowerBiologicsattachment.
● TD Cowen lowered its target to $10 from $13.
Key HighlightsRegeneron Pharmaceuticals (NASDAQ:REGN) jumped about 13 percent on October 30, 2026 as third-quarterRevenuerose 36 percent, with one published account showing a 12.5 percent gain mid-morning and a 13.3 percent gain at the close.Stryker (NYSE:SYK) fell about 10 percent after its chief executive said …
● Health care stocks hit a record high as investors sold chips.
● Non-GAAPEarnings Per Shareof $20.07 topped the $16.24 consensus.
● An expanded Sanofi deal brings $1 billion upfront.
● It raised its full-year 2026 sales forecast.
● AdjustedEarningsof $3.52 a share missed the $3.55 estimate.
● The company raised 2026 product sales guidance to $31.0 billion to $31.3 billion.
● Tariff refunds of $37 million passed to customers reduced reported revenue.
Please wait processing your request...